Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU,China,March 10,2025--SichuanKelun-BiotechBiopharmaceuticalCo.,Ltd. (the"Company") announced that the Company\'s trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conj